1. Investigation of the efficacy of siRNA-mediated KRAS gene silencing in pancreatic cancer therapy.
- Author
-
Küçükekmekci B and Budak Yıldıran FA
- Subjects
- Humans, Cell Line, Tumor, Cell Proliferation drug effects, Cell Proliferation genetics, Genetic Therapy methods, Pancreatic Neoplasms genetics, Pancreatic Neoplasms therapy, Pancreatic Neoplasms pathology, RNA, Small Interfering administration & dosage, RNA, Small Interfering genetics, RNA, Small Interfering pharmacology, Proto-Oncogene Proteins p21(ras) genetics, Proto-Oncogene Proteins p21(ras) metabolism, Metal Nanoparticles chemistry, Gold chemistry, Gene Silencing
- Abstract
Aim: Pancreatic carcinoma is an aggressive cancer that progresses without many symptoms. The difficulty of early diagnosis and an inadequate response to traditional treatments also cause the survival rate of pancreatic cancer to be low. Current research is focusing on methods of diagnosis and treatment, such as gene therapy, to increase survival rates. Small interfering ribonucleic acid (siRNA) has emerged as a promising advanced therapeutic strategy for cancer treatment. This study sought to silence the KRAS gene in the human pancreatic carcinoma cell line using a complex of small interfering ribonucleic acid (siRNA) and gold nanoparticles (AuNP)., Methods: In this study, 25 nM siRNA and gold nanoparticles at 0.5 mg/ml, 0.25 mg/ml, and 0.125 mg/ml concentrations were used to silence the KRAS gene in the CAPAN-1 cell line. Real-time PCR analysis, agarose gel electrophoresis, and double staining were carried out, and xCelligence real-time cell analysis (RTCA) was used to measure proliferation., Results: The PCR analysis revealed crossing point (CP) values of actin beta (ACTB) ranging from 33.04 to 35.98, which was in the expected range for all samples. The interaction between the gold nanoparticle/siRNA complex in the double staining analysis revealed that the most effective concentration of gold nanoparticle was 0.125 mg/ml. The WST-1 technique showed that siRNA/AuPEI cells in application groups had a viability rate of over 90%, indicating no toxicity or side effects. The xCELLigence RTCA® showed that at hour 72, there was a significant difference in proliferation in the 0.5 mg/mL PEI/AuNP-siRNA, 0.25 mg/mL PEI/AuNP-siRNA, and 0.125 mg/mL PEI/AuNP-siRNA application groups compared to the control and siRNA groups ( p < 0.05). By hour 96, all three groups were statistically different from the control and siRNA groups in terms of proliferation ( p < 0.05)., Conclusions: The results of this analysis suggest that the AuPEI/siRNA complex can be effectively used to silence the target gene, but more studies are needed to verify these results., Competing Interests: The authors declare that there are no competing interests., (©2024 Küçükekmekci and Budak Yıldıran.)
- Published
- 2024
- Full Text
- View/download PDF